Document is current
Any future updates will be listed below
-
Authors
Elwing, Jean M. https://orcid.org/0000-0001-6199-1707
Benninger, Christina https://orcid.org/0009-0000-4057-0540
Strachan, Paul https://orcid.org/0009-0004-4267-1918
Triyasakorn, Korawin https://orcid.org/0009-0008-4494-7497
Choren, Marla
Timms, B. Kody https://orcid.org/0009-0007-9661-0231
Reed, Lori https://orcid.org/0000-0003-2896-6010
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 1 January 2026
Accepted: 4 March 2026
First Online: 8 April 2026
Declarations
:
: Jean M. Elwing has served as a consultant for United Therapeutics, Aerovate, Gossamer Bio, Liquidia, Merck, Johnson & Johnson, Insmed, and Pulmovant. She has also participated in clinical research studies funded by United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant, Aerovate, Pharmosa/Liquidia, Johnson & Johnson, Lung LLC, and Pulmovant. Christina Benninger, Paul Strachan, and B. Kody Timms were employees and shareholders of Johnson & Johnson at the time the commentary was developed. Korawin Triyasakom and Marla Choren are employees and shareholders of Johnson & Johnson. Lori Reed has served as a consultant for Johnson & Johnson and United Therapeutics. She has also participated in a speakers’ bureau for Johnson & Johnson, Liquidia, Merck, and United Therapeutics.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
